Open Trials


CompLEEment - An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEED11) in combination with letrozole for the treatment of men and pre/postmenopausal women with HR+, HER2-negative advanced breast cancer with no prior hormonal therapy for advanced disease

E1Z11 - A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NSABP B51 - A randomized Phase III Clinical Trial evaluating post-mastectomy chest wall and Regional Nodal XRT and post-lumpectomy Regional Nodal XRT in patients with positive axillary nodes before Neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after Neodjuvant chemotherapy.

EA1131 - A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

SPI-POZ-201 - Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer

S1416 - Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer


UPCI 13-074 - Randomized Phase II trial of Pre-Operative Gemcitabine and nab Paclitaxel with or without Hydroxychloroquine

PROSPECT/N1048: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery


Alchemist - Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery


CA209-655 - Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices


OPTIMIZE - Study in Patients with Unresectable and Metastatic Melanoma: The Optimize Study (An Observational Study)


UPCI 10-027 - Phase II Study for Curative Intent Treatment for Patients Presenting with Oligometastatic Disease UPCI 10-028 - Phase II Study of Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy for patients with Oligo-recurrent Disease

EAY131 - NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

My Pathway - A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients